

12 May 2016

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement – Listing of Wholly Owned Subsidiary, Clinical Research Corporation

iQnovate Ltd (NSX:IQN) (the Company) advises that further to its announcement in May 2015, the Company remains committed to the Initial Public Offering (IPO) of securities in its wholly owned clinical research and development subsidiary, Clinical Research Corporation Pty Ltd (CRC). The Company is committed to proceed with an IPO of CRC and a proposed listing of CRC's securities on the ASX by the end 2016.

For and on behalf of the Board.



Kelvin Boateng
Company Secretary
iQnovate Ltd

Sydney: Level 7, 222 Clarence Street, Sydney, NSW 2000, Australia • Phone: +61 2 8239 5400
New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA | +1 212 433 2630
London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508

Safe Harbor Statement

Any statements in this announcement that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with iQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE iQnovate Ltd

iQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.